Evoke Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Evoke Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-227	Closed	-$4K	–	1175
2022 Q1	$4K	Hold	227	–	–	﹤0.01%	936
2021 Q4	$3K	Hold	227	–	–	﹤0.01%	977
2021 Q3	$3K	Hold	227	–	–	﹤0.01%	929
2021 Q2	$4K	Buy	+227	New	+$3.08K	﹤0.01%	918

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Evoke Wealth's BCRX Position: Q2 2022 in Review

Evoke Wealth sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 227 shares — an estimated $4K sold.

Evoke Wealth first reported a position in BCRX in Q2 2021 and held it in 4 quarters. The position peaked at $4K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

Evoke Wealth reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Evoke Wealth sold 227 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $4K.
Evoke Wealth first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Evoke Wealth's BioCryst Pharmaceuticals position peaked at $4K in Q1 2022.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Evoke Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.